oral JH2-binding Tyk2 inhibitor

Ph. I in psoriasis complete

backup candidate to BMS-986165 for psoriasis

J. Med. Chem., Dec. 28, 2020

Bristol-Myers Squibb, Princeton, NJ

Bristol Myers Squibb (BMS) oral JH2-domain binding Tyk2 kinase inhibitor


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks